A study reported that OAT2 is highly expressed in Hep G2, particularly in patients with hepatocellular carcinoma treated with platinum compounds, pointing out that the considerable reduction in toxicity when an OAT2 inhibitor is used implies that it may be implicated in platinum uptake via orotic acid, a well-recognized by-product of the pyrimidine biosynthesis pathway in hepatocytes [73]. This evidence concerns the gene SLC22A7 and hepatocellular carcinoma.